Literature DB >> 17658991

Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters.

Sergia Bortolanza1, Pilar Alzuguren, Maria Buñuales, Cheng Qian, Jesus Prieto, Ruben Hernandez-Alcoceba.   

Abstract

The preclinical evaluation of toxicity and antitumor effect of conditionally replicative (oncolytic) adenoviruses is hampered by the inability of human adenoviruses to replicate efficiently in murine cells. The Syrian golden hamster (Mesocricetus auratus) has been suggested as a permissive animal for adenoviral replication, and cancer cell lines derived from various hamster tumors are available. We provide evidence that wild-type adenovirus type 5 is able to infect and replicate in the pancreatic cancer cell lines HaP-T1 and H2T both in vitro and in vivo. Determination of cytopathic effect, viral spread, progeny production, and the expression of late viral proteins indicates that the complete viral cycle of adenovirus takes place, albeit less efficiently than in highly permissive human cancer cell lines A549 and HuH7. Intrahepatic inoculation of HaP-T1 and H2T cells gave rise to tumors in the liver of hamsters that resemble metastases of pancreatic cancer. The growth of HaP-T1-induced nodules was faster compared with those derived from H2T, but both caused progressive liver infiltration and peritoneal dissemination. When adenovirus was inoculated in these lesions, productive replication took place and newly formed infective virions could be recovered 4 days after administration. In conclusion, the Syrian hamster models described here offer the opportunity to evaluate the effect of oncolytic adenoviruses in an immunocompetent animal and may be a valuable tool in the preclinical evaluation of these agents.

Entities:  

Mesh:

Year:  2007        PMID: 17658991     DOI: 10.1089/hum.2007.017

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  14 in total

1.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

2.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

3.  Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Authors:  Maria Bunuales; Eva Garcia-Aragoncillo; Raquel Casado; José Ignacio Quetglas; Sandra Hervas-Stubbs; Sergia Bortolanza; Carolina Benavides-Vallve; Carlos Ortiz-de-Solorzano; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

4.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Authors:  Sergia Bortolanza; Maria Bunuales; Itziar Otano; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz-de-Solorzano; Daniel Perez; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

5.  New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Authors:  J F Spencer; J E Sagartz; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-05-29       Impact factor: 5.987

6.  A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy.

Authors:  Huiping Wang; Fang Wei; Jufeng Zhang; Feng Wang; Huiming Li; Xiafang Chen; Kuangcheng Xie; Yufei Wang; Chuanyuan Li; Qian Huang
Journal:  Tumour Biol       Date:  2012-05-25

7.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

Review 8.  Recent advances in oncolytic virus design.

Authors:  Rubén Hernández-Alcoceba
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.340

9.  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Authors:  L Zhang; F Hedjran; C Larson; G L Perez; T Reid
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987

10.  Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model.

Authors:  S Vijayalingam; Mohan Kuppusamy; T Subramanian; Frank F Strebeck; Cheri L West; Mark Varvares; G Chinnadurai
Journal:  Cancer Gene Ther       Date:  2014-05-30       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.